Proactive Investors - Run By Investors For Investors

OptiBiotix Health now able to pay dividends following capital reorganisation

The cancellation of its share premium account means the company, which develops compounds to tackle obesity, high cholesterol and diabetes, can distribute dividends when it deems it appropriate to do so
The High Court of Justice made an order confirming the capital reduction on February 27

Life sciences business OptiBiotix Health plc (LON:OPTI) told shareholders it is now able to make dividend payments in future, should it want to.

The cancellation of its share premium account has been ratified, creating reserves that are available for distribution to shareholders.

"I am pleased to report that both shareholders and the courts have confirmed the capital reduction. This allows OptiBiotix to make future dividend or 'dividend in specie' distributions to the company's shareholders should it be appropriate to do so. This is part of OptiBiotix's strategy of building value across its divisions and where possible releasing value back to shareholders," said Stephen O'Hara, the chief executive officer of OptiBiotix.

View full OPTI profile View Profile

OptiBiotix Health plc Timeline

Related Articles

September 27 2018
WideCells has undertaken a review of the business to deliver a strategy that will generate revenue, reduce overheads and achieve profitability
May 14 2018
Physiomics' share price surged on a €500,000 contract for its virtual tumour software with Merck KgaA.
CBD oil
November 15 2018
The company’s technology creates nano-scale emulsion mixtures that allow fluids to mix that normally don’t mix, such as CBD oil and water

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use